We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
-1.51%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$393M
AUM Growth
+$25.3M
(+6.9%)
Cap. Flow
+$32.9M
Cap. Flow
% of AUM
8.36%
Top 10 Holdings %
Top 10 Hldgs %
80.79%
Holding
223
New
14
Increased
85
Reduced
52
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MBS ETF
MBB
|
+$10.8M |
| 2 |
Vanguard Mortgage-Backed Securities ETF
VMBS
|
+$10.2M |
| 3 |
Seres Therapeutics
MCRB
|
+$1.62M |
| 4 |
Vuzix
VUZI
|
+$1.34M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
+$1.16M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ouster
OUST
|
+$1.06M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$1.02M |
| 3 |
Travere Therapeutics
TVTX
|
+$897K |
| 4 |
ADC Therapeutics
ADCT
|
+$633K |
| 5 |
RBOT
Vicarious Surgical
RBOT
|
+$548K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 18.05% |
| 2 | Healthcare | 12.08% |
| 3 | Technology | 1.59% |
| 4 | Financials | 1.03% |
| 5 | Industrials | 0.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Collegium Pharmaceutical
COLL
$1.17B
| $730K | 0.19% |
37,000
+28,000
| +311% | +$605K |
|
52
PennyMac Financial
PFSI
$4.43B
| $715K | 0.18% |
11,699
+10,348
| +766% | +$657K |
|
53
Microbot Medical
MBOT
$118M
| $703K | 0.18% |
100,000
| – | – |
|
|
ADAM
54
Adamas Trust
ADAM
$807M
| $674K | 0.17% |
39,553
+10,000
| +34% | +$174K |
|
55
AdaptHealth
AHCO
$1.49B
| $652K | 0.17% |
28,000
+10,000
| +56% | +$242K |
|
56
BioMarin Pharmaceuticals
BMRN
$11.5B
| $618K | 0.16% |
8,000
| – | – |
|
|
MRSN
57
DELISTED
Mersana Therapeutics
MRSN
| $618K | 0.16% |
2,620
+800
| +44% | +$234K |
|
|
BLUE
58
DELISTED
bluebird bio
BLUE
| $612K | 0.16% |
2,470
-78
| -3% | -$22.3K |
|
|
ONIT
59
Onity Group
ONIT
$344M
| $604K | 0.15% |
21,477
| – | – |
|
|
RWT
60
Redwood Trust
RWT
$641M
| $582K | 0.15% |
45,148
| – | – |
|
|
FUSN
61
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $566K | 0.14% |
71,500
| – | – |
|
|
NNDM
62
Nano Dimension
NNDM
$326M
| $564K | 0.14% |
100,000
-35,000
| -26% | -$220K |
|
63
Coherus Oncology
CHRS
$216M
| $562K | 0.14% |
35,000
-16,500
| -32% | -$242K |
|
64
AEye
LIDR
$56.5M
| $547K | 0.14% |
+3,333
| New | +$922K |
|
|
AERI
65
DELISTED
Aerie Pharmaceuticals
AERI
| $542K | 0.14% |
+47,500
| New | +$694K |
|
|
PMT
66
PennyMac Mortgage Investment
PMT
$863M
| $527K | 0.13% |
26,764
| – | – |
|
67
MGIC Investment
MTG
$6.23B
| $505K | 0.13% |
33,775
| – | – |
|
68
Sutro Biopharma
STRO
$391M
| $491K | 0.12% |
2,600
-100
| -4% | -$19K |
|
69
Exelixis
EXEL
$14.1B
| $486K | 0.12% |
23,000
+2,500
| +12% | +$46.4K |
|
70
Invesco Senior Loan ETF
BKLN
$7.19B
| $478K | 0.12% |
21,615
+622
| +3% | +$13.8K |
|
71
iShares Preferred and Income Securities ETF
PFF
$13.3B
| $471K | 0.12% |
12,146
+6,148
| +103% | +$241K |
|
72
Gyre Therapeutics
GYRE
$675M
| $469K | 0.12% |
15,200
-9,133
| -38% | -$301K |
|
73
State Street SPDR Bloomberg Convertible Securities ETF
CWB
$5.78B
| $467K | 0.12% |
5,477
-53
| -1% | -$4.57K |
|
74
iShares Mortgage Real Estate ETF
REM
$559M
| $466K | 0.12% |
12,885
+286
| +2% | +$10.4K |
|
75
PTC Therapeutics
PTCT
$6.52B
| $465K | 0.12% |
12,500
+2,500
| +25% | +$103K |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q3 2021 Portfolio in Review
As of Q3 2021, AlphaCentric Advisors held 223 positions worth $393M, up 6.9% from $368M the previous quarter. Its ten largest holdings account for 81% of the portfolio.
AlphaCentric Advisors deployed $32.9M of net new capital in Q3 2021, opening 14 new positions and adding to 85 existing holdings. Its largest new stake was Seres Therapeutics: 8,275 shares worth $1.15M.
By sector, the portfolio is most concentrated in Real Estate at 18% of assets, down from 19% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $1.02M trimmed.
- AlphaCentric Advisors's largest Q3 2021 buy was Seres Therapeutics: 8,275 shares worth $1.15M.
- AlphaCentric Advisors added most to iShares MBS ETF in Q3 2021, an estimated $10.8M increase.
- AlphaCentric Advisors's biggest Q3 2021 reduction was Regeneron Pharmaceuticals, cutting an estimated $1.02M.
- AlphaCentric Advisors fully exited Ouster in Q3 2021, selling an estimated $1.06M.
- AlphaCentric Advisors's ten largest holdings make up 81% of its $393M portfolio in Q3 2021.
- AlphaCentric Advisors opened 14 new positions and closed 29 in Q3 2021.
- AlphaCentric Advisors's portfolio value rose 6.9% quarter-over-quarter to $393M.
Based on AlphaCentric Advisors's 13F filing for Q3 2021, filed 9 Mar 2022.